A method for preparing newcastle disease virus
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- JIANGSU KANION PHARMA CO LTD
- Filing Date
- 2024-11-19
- Publication Date
- 2026-05-29
AI Technical Summary
In the current technology, the large-scale production and purification process of Newcastle disease virus is not yet mature, making it difficult to prepare virus samples with high activity titers, low impurities, controllable quality, and small batch-to-batch differences, which poses a challenge, especially in the field of oncolytic virus anti-tumor therapy.
Newcastle disease virus was produced by serum-free, fully suspended culture of HEK293F cells and purified by clarification filtration, nuclease treatment, affinity chromatography, ultrafiltration concentration, and molecular sieve chromatography. UniGel-65 Heparin was used as the chromatographic packing material for affinity chromatography.
It achieves viral titers higher than 1×10⁸ PFU/mL, low impurity content, meets the needs of preclinical and clinical trials, improves viral quality uniformity and controllability, and is suitable for large-scale production.
Smart Images
Figure BDA0005144785740000101 
Figure BDA0005144785740000102 
Figure BDA0005144785740000111